Portfolio News

Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced that it will present new research findings for its ST1 monoclonal antibody (mAb) therapeutic program during a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018, being held April 14-18, 2018, at McCormick Place in Chicago. Read more >>
Read more...

Aircuity Adds Chief Growth Officer and Product Manager to Focus on Next Phase of Growth & Expansion of its 2.0 Platform

Aircuity, creator of measurably better environments, announces the addition of a Chief Growth Officer and a Product Manager; as the company implements its strategy for growth and maximizes value for clients. These additions will allow the company to leverage and expand its Aircuity 2.0 platform. Read more >>
Read more...

Respiratory Motion, Inc. is excited to announce FDA clearance for use of the ExSpiron™ 1Xi Minute Ventilation Monitor in Pediatric Patients

Respiratory Motion, Inc. reported today that FDA clearance was received for the newest version of its ExSpiron Minute Ventilation (MV) monitoring system on Friday March 16th and announced its plan to launch the new ExSpiron at the Society for Pediatric Anesthesia-American Academy of Pediatrics in Phoenix, March 23-25. Read more >>
Read more...